Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

The vaccine contains inactivated or subunit antigens derived from the Influenza Virus B/Austria/1359417/2021‑Like strain and Influenza A/Vic. When injected, these antigens are recognized by the immune system, prompting B‑cell and T‑cell activation and the production of strain‑specific antibodies that neutralize the virus upon exposure.

The prescribed dose of Influvac is determined by the treating healthcare professional based on age, health status and local immunization guidelines. Typically a single intramuscular injection is administered each influenza season, with a second dose only if recommended for certain age groups or immunocompromised patients.

Influvac may be administered to pregnant or lactating individuals when the potential benefits outweigh any theoretical risks. Current data do not indicate specific safety concerns, but vaccination decisions should be made in consultation with a qualified healthcare provider who can evaluate individual circumstances.

To place an order, submit an enquiry on the Influvac product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Influvac is a trivalent (or quadrivalent) inactivated influenza vaccine containing the B/Austria/1359417/2021‑Like strain and A/Vic, offering broad protection similar to other licensed flu vaccines. Compared with live‑attenuated nasal sprays, Influvac is administered by injection, has a well‑established safety profile, and is suitable for a wider range of age groups, including those with certain contraindications to live vaccines.

Influvac must be stored at 2 °C to 8 °C (refrigerated) in its original packaging, protected from light. The vaccine should not be frozen or shaken, and any vial that has been frozen or appears cloudy should be discarded. Maintain the cold chain during transport and handling to preserve potency.

Influvac is given by a single intramuscular injection, typically into the deltoid muscle of the upper arm. Subcutaneous administration is also acceptable if intramuscular injection is not feasible. The injection should be performed by a qualified healthcare professional using aseptic technique and appropriate needle size.

Although rare, serious adverse events after Influvac may include anaphylaxis, Guillain‑Barré syndrome, and high‑grade fever or seizures. Recipients should be observed for at least 15 minutes after vaccination, and any signs of severe allergic reaction—such as difficulty breathing, swelling of the face or throat, or rapid pulse—require immediate medical attention.

Individuals with a known severe allergy to any component of Influvac, including egg protein if present, or those who have experienced a previous anaphylactic reaction to an influenza vaccine, should not receive this product. Additionally, persons with acute moderate or severe illness should defer vaccination until recovery.